Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 8 for:    2004-06

Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00130507
Recruitment Status : Terminated (A new alternative treatment caused the decrease in the rhythm of recruitment.)
First Posted : August 15, 2005
Last Update Posted : February 26, 2019
Sponsor:
Collaborator:
Hoffmann-La Roche
Information provided by (Responsible Party):
Spanish Breast Cancer Research Group

Tracking Information
First Submitted Date  ICMJE August 12, 2005
First Posted Date  ICMJE August 15, 2005
Last Update Posted Date February 26, 2019
Actual Study Start Date  ICMJE November 4, 2005
Actual Primary Completion Date June 2009   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 25, 2019)
Clinical benefit rate [ Time Frame: Through study completion, an average of 1 year ]
Clinical benefit rate is defined as the rate of objective responses (complete responses and partial responses to treatment) and stabilizations, with a minimum duration of 24 weeks.
Original Primary Outcome Measures  ICMJE
 (submitted: August 12, 2005)
Clinical benefit rate (lasting for at least 24 weeks.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 25, 2019)
  • Time to progression (TTP) [ Time Frame: Through study completion, an average of 1 year ]
    Tumor assessments will be performed until disease progression in order to evaluate the TTP. TTP is defined as the time from the date of the first dose to the first date of objectively determined progressive disease. For patients not known to have objectively-determined progressive disease, TTP will be censored at the date of the last objective progression-free assessment. For patients who receive subsequent systemic anticancer therapy (after discontinuation from the study treatment) prior to objective disease progression, TTP will be censored at the date of last objective progression-free assessment prior to the initiation of postdiscontinuation systemic anticancer therapy.
  • Objective Response Rate (ORR) [ Time Frame: Through study completion, an average of 1 year ]
    Tumor response will be assessed using RECIST criteria. The best response across all treatment will be recorded. ORR is defined as the percentage of patients with a complete or partial response out of the patients who had measurable disease at baseline.
  • Response Duration (RD) [ Time Frame: Through study completion, an average of 1 year ]
    RD is defined as the time from the date when the measurement criteria are met for complete response (CR) or partial response (PR) (whichever status is recorded first) until the date of first observation of disease progression or death occurred. For responding patients not known to have died as of the data cut-off date and who do not have progression, duration of response will be censored at the date of last visit with adequate assessment. For responding patients who receive subsequent anticancer therapy (after discontinuation from the study treatment) prior to progression, duration of response will be censored at the date of last visit with adequate assessment prior to the initiation of post-discontinuation anticancer therapy.
  • The Number of Participants Who Experienced Adverse Events (AE) [ Time Frame: Through study completion, an average of 1 year ]
    All AE suffered by patients will be recorded and graduated by the NCI CTCAE v1.0.
  • Overall Survival (OS) [ Time Frame: Through study completion, an average of 1 year ]
    OS was defined as the time elapsed from first treatment until death from any cause.
Original Secondary Outcome Measures  ICMJE
 (submitted: August 12, 2005)
  • Time to progression.
  • Overall response rate.
  • Response duration.
  • Safety profile.
  • Overall survival.
  • Quality of life.
  • Election of best treatment arm.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab
Official Title  ICMJE Randomized Trial to Assess the Benefit of Adding Trastuzumab to Capecitabine and Vinorelbine as Second Line for HER2positive Breast Cancer Patients With Locally Advanced or Metastatic Disease, Previously Treated With Trastuzumab and Taxanes
Brief Summary Eligible patients must receive vinorelbine plus capecitabine, with or without trastuzumab, until disease progression or unbearable toxicity. Cycles will be administered every 3 weeks.Human epidermal growth factor receptor 2 (HER2) status must be locally assessed by immunohistochemistry (IHC). All 3+ patients are eligible. In 2+ patients, HER2 status must be confirmed by fluorescence in situ hybridization (FISH).
Detailed Description

Principal outcome is clinical benefit (complete + partial responses + stable disease). Sample size in each arm has been estimated with the Fleming method. Previous data show a clinical benefit rate of vinorelbine plus capecitabine around 50%. The researchers assume trastuzumab can increase it by 20%. With an alpha error of 0.05 and 80% power, 37 patients per arm are needed.

This is a randomised phase II trial. With a minimum expected benefit rate of 50%, at least 36 patients are needed to choose, with a 90% of probability to be right, the best treatment arm, providing it increases benefit rate at least by 15%.

Assuming a drop-out rate of 10%, the total number of patients needed is 82, 41 per treatment arm.

Patients will be stratified as per investigational site, and presence of visceral metastatic lesion (liver, lung, pleura, heart, peritoneum, suprarenal glands). All patients must receive 2 cycles. If no disease progression is detected, treatment must continue until progression or unbearable toxicity.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Breast Cancer
Intervention  ICMJE
  • Drug: Vinorelbine
    Other Name: Navelbine
  • Drug: Capecitabine
    Other Name: Xeloda
  • Drug: Trastuzumab
    Other Name: Herceptin
Study Arms  ICMJE
  • Active Comparator: Arm A: VX
    Vinorelbine and capecitabine (VX): vinorelbine 25 mg/m2 iv, days 1 and 8 each cycle (21 days), followed of capecitabine 825 mg/m2, orally, twice a day, days 1-14 each cycle (21 days).
    Interventions:
    • Drug: Vinorelbine
    • Drug: Capecitabine
  • Experimental: Arm B: VXH
    Vinorelbine, capecitabine and trastuzumab (VXH): vinorelbine 25 mg/m2 iv, days 1 and 8 each cycle (21 days), followed of capecitabine 825 mg/m2, orally, twice a day, days 1-14 each cycle (21 days) and trastuzumab 4 mg/kg iv (loading dose first week), followed by 2 mg/kg weekly.
    Interventions:
    • Drug: Vinorelbine
    • Drug: Capecitabine
    • Drug: Trastuzumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: October 25, 2011)
14
Original Enrollment  ICMJE
 (submitted: August 12, 2005)
82
Actual Study Completion Date  ICMJE July 25, 2009
Actual Primary Completion Date June 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Written informed consent.
  • Women older than 18 years old.
  • HER2 positive breast cancer with histological diagnoses.
  • Non-operable locally advanced or metastatic disease, previously treated with trastuzumab and taxanes.
  • Measurable or non-measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST).
  • Disease progression during or after treatment with trastuzumab and taxanes.
  • Maximum of 1 previous chemotherapy line for advanced or metastatic disease.
  • Previous radiotherapy is allowed if radiated area is not the only documented lesion.
  • At least 4 weeks since the last administration of antineoplastic treatment and all toxicities resolved.
  • Performance status Eastern Cooperative Oncology Group (ECOG) >=2.
  • Life expectancy of at least 12 weeks.
  • Left Ventricular Ejection Fraction (LVEF) evaluation (>=50%) in previous 4 weeks.
  • Hematology:

    • neutrophils >=1.5 x 10e9/l;
    • platelets >= 100 x 10e9/l;
    • hemoglobin >= 10 mg/dl
  • Hepatic function:

    • total bilirubin <= 1.5 x under normal limit (UNL);
    • Aspartate aminotransferase (SGOT) and Alanine aminotransferase (SGPT) and alkaline phosphatase <= 2.5 x UNL, or <=5 x UNL if hepatic lesions present
  • Renal function:

    • creatinine <= 175 µmol/l (2 mg/dl);
    • creatinine clearance >= 60 ml/min.
  • Patients able to comply with treatment and follow-up.
  • Negative pregnancy test in the previous 14 days. Adequate contraceptive method during treatment and up to 3 months after finalised.
  • Brain metastatic lesions are allowed provided all other criteria are met.
  • Male who met inclusion criteria are eligible.

Exclusion Criteria:

  • History of hypersensitivity to vinorelbine, trastuzumab, rat proteins or trastuzumab components.
  • History of dyspnea at rest, or chronic oxygen therapy required.
  • Active infection.
  • Second malignancy, except for cervical in situ carcinoma, basal skin carcinoma, adequately treated. Previous malignancies with a 5 year disease free survival are allowed.
  • Pregnant or lactating women.
  • Any other serious medical pathology, such as congestive heart failure, unstable angina, history of myocardial infarction during the previous year, uncontrolled hypertension or high risk arrhythmias.
  • History of neurological or psychiatric disorders, which could preclude the patients to free informed consent.
  • Active uncontrolled infection.
  • Active peptic ulcer, unstable diabetes mellitus.
  • Concomitant treatment with other investigational products. Participation in other clinical trials with a non-marketed drug in the 30 previous days before randomization.
  • Concomitant treatment with other therapy for cancer.
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Spain
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00130507
Other Study ID Numbers  ICMJE GEICAM 2004-06
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Spanish Breast Cancer Research Group
Study Sponsor  ICMJE Spanish Breast Cancer Research Group
Collaborators  ICMJE Hoffmann-La Roche
Investigators  ICMJE
Study Director: Study Director Hospital Clinic i Provincial
PRS Account Spanish Breast Cancer Research Group
Verification Date February 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP